SCHEMBL213708

SCHEMBL213708

CC(c1ccccc1)N(C(=O)c1nc[nH]c1C(N)=O)c1nc2ccccc2[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.40
HTT P42858 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 5/20 0.36
KDM4E B2RXH2 2/20 0.36
MAPT P10636 2/20 0.36
PAX8 Q06710 1/20 0.36
ALDH1A1 P00352 3/20 0.35
GAA P10253 1/20 0.35
POLB P06746 1/20 0.35
LMNA P02545 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34
TRPM8 Q7Z2W7 1/20 0.34
MEN1 O00255 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
ALOX5 P09917 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL213760 0.81 POLB (0.39) HPGDHTTSMN1; SMN2NPC1RAB9A
SCHEMBL216075 0.78 POLB (0.38) HPGDHTTSMN1; SMN2KMT2AKDM4E
SCHEMBL216070 0.78 POLB (0.47) HPGDHTTSMN1; SMN2NPC1RAB9A
SCHEMBL213971 0.78 PAX8 (0.43) HPGDHTTSMN1; SMN2NPC1RAB9A
SCHEMBL214715 0.77 POLB (0.40) HPGDHTTSMN1; SMN2NPC1RAB9A
SCHEMBL217154 0.76 POLB (0.36) HPGDHTTSMN1; SMN2NPC1RAB9A
SCHEMBL214873 0.75 LMNA (0.39) HPGDHTTSMN1; SMN2NPC1RAB9A
SCHEMBL215369 0.75 POLB (0.41) HPGDHTTSMN1; SMN2NPC1RAB9A
SCHEMBL214790 0.75 HPGD (0.37) HPGDHTTSMN1; SMN2NPC1RAB9A
SCHEMBL215785 0.75 POLB (0.41) HPGDHTTSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US claimed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US claimed
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 HPGD 3138/4885HTT 1059/4885SMN1; SMN2 2516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.